Basic Information


GTO ID GTC3225
Trial ID NCT05606965
Disease Influenza
TherapymRNA vaccine
Treatment mRNA-1010
PhasePhase2
Recruitment statusCompleted
TitlePhase 2, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 and Comparator Seasonal Influenza Vaccines in Healthy Adults
Year2022
CountryUnited States
Company sponsorModernaTX, Inc.
Other ID(s)mRNA-CRID-003
Vector information
Vectorlipid nanoparticle

Clinical Result

Cohort1: mRNA-1010_Age Group 18-50 years
Administration route intramuscular injection
Age Adult, Older_Adult
Cohort2: Egg-based Quadrivalent Influenza Vaccine
Administration route intramuscular injection
Age Adult, Older_Adult
Cohort3: Adjuvanted Quadrivalent Influenza Vaccine
Administration route intramuscular injection
Age Adult, Older_Adult
Cohort4: Inactivated Influenza Vaccine
Administration route intramuscular injection
Age Adult, Older_Adult
Cohort5: mRNA-1010_Age Group 65-80 years
Administration route intramuscular injection
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph